Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/7UFQJaR3O0k/263932.php
Saturday 27 July 2013
Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections
In the commenting procedure on early benefit assessment pursuant to the German Act on the Reform of the Market for Medicinal Products (AMNOG), under certain circumstances drug manufacturers may submit to the Federal Joint Committee (G-BA) additional documents for dossiers. The Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed such additional information for two studies comparing the antibiotic fidaxomicin, which is used for diarrhoea caused by Clostridium difficile infections, with vancomycin...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment